Disentangling empathy for psychological and physical pain in borderline personality disorder: the interplay with clinical features and emotional competenceEUROPEAN JOURNAL OF PSYCHIATRYIF1.52026-01-011PRE
Profiling electrophysiological and linguistic markers: implications for clinical and functional outcome in schizophrenia分析电生理和语言标记:对精神分裂症临床和功能结局的影响NEUROPSYCHOLOGIAIF22025-12-010PRE
Adverse childhood experiences differently affect Theory of Mind brain networks in schizophrenia and healthy controlsJOURNAL OF PSYCHIATRIC RESEARCHIF3.22024-04-011PRE
The kynurenine pathway in treatment-resistant schizophrenia at the crossroads between pathophysiology and pharmacotherapySCHIZOPHRENIA RESEARCHIF3.52024-02-0113PRE
Improving outcome of treatment-resistant schizophrenia: effects of cognitive remediation therapyEUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCEIF3.72023-12-192PRE
The different effect of adverse childhood experiences on Theory of Mind brain networks in schizophrenia and healthy controlsEUROPEAN PSYCHIATRYIF6.72023-07-190OAAI
Cognitive reserve profiles are associated with outcome in schizophrenia.JOURNAL OF THE NEUROLOGICAL SCIENCESIF3.22022-12-012PRE
Deconstructing heterogeneity in schizophrenia through language: a semi-automated linguistic analysis and data-driven clustering approachSCHIZOPHRENIAIF4.12022-11-2911OAAI
Modeling the interplay of age at onset and sex on cognition in SchizophreniaASIAN JOURNAL OF PSYCHIATRYIF4.52022-09-016PRE
Treatment-resistance as a predictor of cognitive remediation outcome in schizophreniaEUROPEAN NEUROPSYCHOPHARMACOLOGYIF6.72021-12-011PRE
Clozapine to N-Desmethylclozapine ratio in treatment resistant schizophrenia: clinical implications from psychopathology to cognitionEUROPEAN NEUROPSYCHOPHARMACOLOGYIF6.72021-12-011PRE
Targeting quality of life in schizophrenia: the fil rouge between metabolic syndrome and anxietyEUROPEAN NEUROPSYCHOPHARMACOLOGYIF6.72021-12-010PRE
Words toward recovery: analyzing speech determinants of quality of life in chronic schizophreniaEUROPEAN NEUROPSYCHOPHARMACOLOGYIF6.72021-12-010PRE
Combined effect of treatment-resistance and autistic traits on sociocognitive abilities in schizophreniaEUROPEAN NEUROPSYCHOPHARMACOLOGYIF6.72021-12-010PRE
Longitudinal course of cognition in schizophrenia: Does treatment resistance play a role?JOURNAL OF PSYCHIATRIC RESEARCHIF3.22021-09-0113PRE
Factors affecting cognitive remediation outcome in schizophrenia: The role of treatment resistanceEUROPEAN PSYCHIATRYIF6.72021-08-130OAAI
Theory of mind and stereotypic behavior promote daily functioning in patients with schizophreniaAUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRYIF3.72021-08-114PRE
Disentangling Cognitive Heterogeneity in Psychotic Spectrum DisordersASIAN JOURNAL OF PSYCHIATRYIF4.52021-06-013PREAI
Functional benefits of co-occurring autistic symptoms in schizophrenia is delimited by symptom severityJOURNAL OF PSYCHIATRIC RESEARCHIF3.22021-05-0113PREAI
White matter integrity, clinical symptoms and quality of life in schizophrenia: a DTI studyEUROPEAN NEUROPSYCHOPHARMACOLOGYIF6.72021-03-010PREAI